CRA’s Rare Disease Spotlight team is excited to present Project LEOPARD, an ongoing assessment of the long-term evolution and outlook for patient access in rare disease. In this first installment, Cécile Matthews and Bhavesh Patel explore what we can expect for patient access in established, or competitive, rare diseases, and how life sciences companies can successfully navigate the future environment for this category of rare disease. Learn more about Project LEOPARD and subscribe to our rare disease insights.
From spreadsheet to strategy: How leading pharma companies transform annual brand planning into competitive advantage
Insight as your ABP backbone Annual Brand Planning (ABP) should not feel like a reinvention exercise every year, particularly for established brands. Instead,...